{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:06:22Z","timestamp":1793271982406,"version":"4.5.0"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2021,10,12]]},"abstract":"\n Importance<\/jats:title>\n Postmenopausal vaginal symptoms are common and frequently detrimental to a woman\u2019s quality of life. Fractional carbon dioxide vaginal laser is increasingly offered as a treatment, but the efficacy remains unproven.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine the efficacy of fractional carbon dioxide laser for treatment of vaginal symptoms associated with menopause.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A double-blind, randomized, sham-controlled trial with 12-month follow-up was undertaken at a single tertiary referral hospital in Sydney, Australia. Enrollment commenced on September 19, 2016, with final follow-up on June 30, 2020. Participants were postmenopausal women with vaginal symptoms substantive enough to seek medical treatment. Of 232 participants approached, 85 were randomized.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Three treatments using a fractional microablative carbon dioxide laser system performed 4 to 8 weeks apart, with 43 women randomized to the laser group and 42 to the sham group.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The co\u2013primary outcomes were symptom severity assessed using a visual analog scale (VAS; range, 0-100; 0 indicates no symptoms and 100 indicates the most severe symptoms) and the Vulvovaginal Symptom Questionnaire (VSQ; range, 0-20; 0 indicates no symptoms and 20 indicates the most severe symptoms) at 12 months. The minimal clinically important difference was specified as a 50% decrease in both VAS and VSQ severity scores. There were 5 prespecified secondary outcomes, including quality of life (range, 0-100; higher scores indicate better quality of life), the Vaginal Health Index Score (range, 5-25; higher scores indicate better health), and vaginal histology (premenopausal or postmenopausal status).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 85 randomized participants (mean [SD] age, 57 [8] years), 78 (91.7%) completed the 12-month follow-up. From baseline to 12 months, there was no significant difference between the carbon dioxide laser group and the sham group in change in symptom severity (VAS score for overall vaginal symptoms: \u201317.2 vs \u201326.6; difference, 9.4 [95% CI, \u201328.6 to 47.5]; VAS score for the most severe symptom: \u201324.5 vs \u201320.4; difference \u20134.1 [95% CI, \u201332.5 to 24.3]; VSQ score: \u20133.1 vs \u20131.6; difference, \u20131.5 [95% CI, \u20135.9 to 3.0]). There were no significant differences between the laser and sham group in the mean quality of life score (6.3 vs 1.4; difference, 4.8 [95% CI, \u20133.9 to 13.5]) and Vaginal Health Index Score (0.9 vs 1.3; difference, \u20130.4 [95% CI, \u20134.3 to 3.6]) or in histological comparisons between laser and sham treatment groups. There were 16 adverse events in the laser group and 17 in the sham group, including vaginal pain\/discomfort (44% vs 68%), spotting, discharge, and lower urinary tract symptoms. No severe adverse events were reported in either group.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Among women with postmenopausal vaginal symptoms, treatment with fractional carbon dioxide laser vs sham treatment did not significantly improve vaginal symptoms after 12 months.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n Australian and New Zealand Clinical Trials Registry:\n ACTRN12616001403426<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2021.14892","type":"journal-article","created":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T17:29:16Z","timestamp":1634491756000},"page":"1381","source":"Crossref","is-referenced-by-count":124,"title":["Effect of Fractional Carbon Dioxide Laser vs Sham Treatment on Symptom Severity in Women With Postmenopausal Vaginal Symptoms"],"prefix":"10.1001","volume":"326","author":[{"given":"Fiona G.","family":"Li","sequence":"first","affiliation":[{"name":"School of Women\u2019s and Children\u2019s Health, UNSW Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Maheux-Lacroix","sequence":"additional","affiliation":[{"name":"School of Women\u2019s and Children\u2019s Health, UNSW Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Deans","sequence":"additional","affiliation":[{"name":"School of Women\u2019s and Children\u2019s Health, UNSW Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Nesbitt-Hawes","sequence":"additional","affiliation":[{"name":"School of Women\u2019s and Children\u2019s Health, UNSW Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Budden","sequence":"additional","affiliation":[{"name":"School of Women\u2019s and Children\u2019s Health, UNSW Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Nguyen","sequence":"additional","affiliation":[{"name":"School of Women\u2019s and Children\u2019s Health, UNSW Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire Y.","family":"Lim","sequence":"additional","affiliation":[{"name":"School of Women\u2019s and Children\u2019s Health, UNSW Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Song","sequence":"additional","affiliation":[{"name":"School of Women\u2019s and Children\u2019s Health, UNSW Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalla","family":"McCormack","sequence":"additional","affiliation":[{"name":"School of Women\u2019s and Children\u2019s Health, UNSW Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Lyons","sequence":"additional","affiliation":[{"name":"School of Women\u2019s and Children\u2019s Health, UNSW Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Segelov","sequence":"additional","affiliation":[{"name":"School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Abbott","sequence":"additional","affiliation":[{"name":"School of Women\u2019s and Children\u2019s Health, UNSW Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"joi210095r1","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/GME.0000000000001752","article-title":"Genitourinary syndrome of menopause: a systematic review on prevalence and treatment.","volume":"28","author":"Mili","year":"2021","journal-title":"Menopause"},{"issue":"3","key":"joi210095r2","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s12020-017-1470-7","article-title":"Sexual function and sex hormones in breast cancer patients.","volume":"60","author":"Gambardella","year":"2018","journal-title":"Endocrine"},{"issue":"1","key":"joi210095r3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10103-014-1677-2","article-title":"Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment.","volume":"30","author":"Zerbinati","year":"2015","journal-title":"Lasers Med Sci"},{"issue":"3","key":"joi210095r4","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.jmig.2020.08.001","article-title":"The efficacy of vaginal laser and other energy-based treatments on genital symptoms in postmenopausal women: a systematic review and meta-analysis.","volume":"28","author":"Li","year":"2021","journal-title":"J Minim Invasive Gynecol"},{"issue":"2","key":"joi210095r5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/ajo.2018.58.issue-2","article-title":"The evidence for laser treatments to the vulvo-vagina: making sure we do not repeat past mistakes.","volume":"58","author":"Song","year":"2018","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"4","key":"joi210095r6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jacbts.2016.03.009","article-title":"Drugs, devices, and the FDA: part 2: an overview of approval processes: FDA approval of medical devices.","volume":"1","author":"Van Norman","year":"2016","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"joi210095r8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/GME.0000000000000955","article-title":"Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women.","volume":"25","author":"Cruz","year":"2018","journal-title":"Menopause"},{"issue":"1","key":"joi210095r9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/GME.0000000000001416","article-title":"A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: the VeLVET trial.","volume":"27","author":"Paraiso","year":"2020","journal-title":"Menopause"},{"issue":"8","key":"joi210095r10","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1097\/GME.0000000000001333","article-title":"Fractional CO2 laser versus promestriene and lubricant in genitourinary syndrome of menopause: a randomized clinical trial.","volume":"26","author":"Politano","year":"2019","journal-title":"Menopause"},{"issue":"9","key":"joi210095r11","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1097\/GME.0b013e318282600b","article-title":"The Vulvovaginal Symptoms Questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women.","volume":"20","author":"Erekson","year":"2013","journal-title":"Menopause"},{"issue":"5","key":"joi210095r12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamainternmed.2018.0116","article-title":"Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial.","volume":"178","author":"Mitchell","year":"2018","journal-title":"JAMA Intern Med"},{"key":"joi210095r13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1477-7525-11-61","article-title":"Construct validity of the Assessment of Quality of Life - 6D (AQoL-6D) in community samples.","volume":"11","author":"Allen","year":"2013","journal-title":"Health Qual Life Outcomes"},{"issue":"11","key":"joi210095r14","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1111\/j.1743-6109.2008.00967.x","article-title":"Assessing sexual function in well women: validity and reliability of the Monash Women\u2019s Health Program Female Sexual Satisfaction Questionnaire.","volume":"5","author":"Davison","year":"2008","journal-title":"J Sex Med"},{"key":"joi210095r15","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/0378-5122(95)00956-6","article-title":"Urogenital ageing: an old problem newly recognized.","volume":"22","author":"Bachmann","year":"1995","journal-title":"Maturitas"},{"issue":"1","key":"joi210095r16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00192-014-2464-0","article-title":"Assessment of vaginal atrophy: a review.","volume":"26","author":"Weber","year":"2015","journal-title":"Int Urogynecol J"},{"issue":"8","key":"joi210095r17","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1097\/GME.0000000000000401","article-title":"Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study.","volume":"22","author":"Salvatore","year":"2015","journal-title":"Menopause"},{"issue":"1","key":"joi210095r18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/asj\/sjy087","article-title":"Treatment to external labia and vaginal canal with CO2 laser for symptoms of vulvovaginal atrophy in postmenopausal women.","volume":"39","author":"Samuels","year":"2019","journal-title":"Aesthet Surg J"},{"issue":"3","key":"joi210095r19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.5301\/je.5000184","article-title":"Microablative fractional CO2 laser improves dyspareunia related to vulvovaginal atrophy: a pilot study.","volume":"6","author":"Salvatore","year":"2014","journal-title":"J Endometr Pelvic Pain Disord"},{"issue":"4","key":"joi210095r20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3109\/13697137.2014.899347","article-title":"A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study.","volume":"17","author":"Salvatore","year":"2014","journal-title":"Climacteric"},{"issue":"4","key":"joi210095r21","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.fertnstert.2004.03.046","article-title":"Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial.","volume":"82","author":"Abbott","year":"2004","journal-title":"Fertil Steril"},{"issue":"9","key":"joi210095r22","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jclinepi.2013.03.017","article-title":"Multiple imputation of missing values was not necessary before performing a longitudinal mixed-model analysis.","volume":"66","author":"Twisk","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"joi210095r24","doi-asserted-by":"publisher","first-page":"890.e1","DOI":"10.1016\/j.ajog.2020.06.032","article-title":"A cost-effectiveness analysis of vaginal carbon dioxide laser therapy compared with standard medical therapies for genitourinary syndrome of menopause-associated dyspareunia.","volume":"223","author":"Wallace","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"joi210095r25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/GME.0000000000001261","article-title":"Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.","volume":"26","author":"Constantine","year":"2019","journal-title":"Menopause"},{"issue":"6","key":"joi210095r26","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/bjo.v128.6","article-title":"Vaginal Er:YAG laser application in the menopausal ewe model: a randomised estrogen and sham-controlled trial.","volume":"128","author":"Mackova","year":"2021","journal-title":"BJOG"},{"issue":"9","key":"joi210095r27","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/lsm.v51.9","article-title":"Laser vaginal tightening complications: report of three cases.","volume":"51","author":"Al-Badr","year":"2019","journal-title":"Lasers Surg Med"},{"issue":"4","key":"joi210095r28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/GME.0000000000001293","article-title":"Rethinking the techno vagina: a case series of patient complications following vaginal laser treatment for atrophy.","volume":"26","author":"Gordon","year":"2019","journal-title":"Menopause"},{"issue":"1","key":"joi210095r29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00128071-200304010-00001","article-title":"Can thermal lasers promote skin wound healing?","volume":"4","author":"Capon","year":"2003","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"joi210095r30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/lsm.v39:2","article-title":"In vivo histological evaluation of a novel ablative fractional resurfacing device.","volume":"39","author":"Hantash","year":"2007","journal-title":"Lasers Surg Med"},{"key":"joi210095r7","unstructured":"Statement from FDA Commissioner Scott Gottlieb, MD, on efforts to safeguard women\u2019s health from deceptive health claims and significant risks related to devices marketed for use in medical procedures for \u201cvaginal rejuvenation.\u201d News release. US Food and Drug Administration. Updated August 2, 2018. Accessed September 19, 2021. https:\/\/www.fda.gov\/medicaldevices\/safety\/alertsandnotices\/ucm615013.htm"},{"key":"joi210095r23","unstructured":"Urogynecologic Surgical Mesh Implants. US Food and Drug Administration. Updated October 7, 2019. Accessed September 20, 2020. https:\/\/www.fda.gov\/medical-devices\/implants-and-prosthetics\/urogynecologic-surgical-mesh-implants"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2784960\/jama_li_2021_oi_210095_1709057914.13534.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T11:00:29Z","timestamp":1709118029000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2784960"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":30,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2021,10,12]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2021.14892","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,12]]}}}